

# Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply

Gordon, Caroline

DOI:

[10.1093/rheumatology/key170](https://doi.org/10.1093/rheumatology/key170)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Gordon, C 2018, 'Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply', *Rheumatology (Oxford)*. <https://doi.org/10.1093/rheumatology/key170>

[Link to publication on Research at Birmingham portal](#)

## Publisher Rights Statement:

Checked for eligibility 12/06/2018

This is a pre-copyedited, author-produced version of an article accepted for publication in *Rheumatology* following peer review. The version of record

Caroline Gordon, Maame-Boatema Amissah-Arthur, Mary Gayed, Sue Brown, Ian N Bruce, David D'Cruz, Benjamin Empson, Bridget Griffiths, David Jayne, Munther Khamashta, Liz Lightstone, Peter Norton, Yvonne Norton, Karen Schreiber, David Isenberg, British Society for Rheumatology Standards, Audit and Guidelines Working Group; Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply, *Rheumatology*, , key170,

is available online at: <https://doi.org/10.1093/rheumatology/key170>

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# **Response to comments by Ruiz-Irastorza et al. on the British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults**

Caroline Gordon<sup>1,2,3</sup>, Maame-Boatema Amissah-Arthur<sup>1</sup>, Mary Gayed<sup>1,3</sup>, Sue Brown<sup>4</sup>, Ian N. Bruce<sup>5,6</sup>, David D'Cruz<sup>7</sup>, Benjamin Empson<sup>8</sup>, Bridget Griffiths<sup>9</sup>, David Jayne<sup>10,11</sup>, Munther Khamashta<sup>12,13</sup>, Liz Lightstone<sup>14</sup>, Peter Norton<sup>15</sup>, Yvonne Norton<sup>15</sup>, Karen Schreiber<sup>16,17</sup>, David Isenberg<sup>18</sup> for the British Society for Rheumatology Standards, Audit and Guidelines Working Group

<sup>1</sup>Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

<sup>2</sup>Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK

<sup>3</sup>Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

<sup>4</sup>Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, UK

<sup>5</sup>Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre.

<sup>6</sup>The Kellgren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University Foundation Trust, Manchester UK

<sup>7</sup>Louise Coote Lupus Unit, Guy's Hospital, London, UK

<sup>8</sup>Laurie Pike Health Centre, Modality Partnership, Birmingham, UK

<sup>9</sup>Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne, UK

<sup>10</sup>Department of Medicine, University of Cambridge, Cambridge, UK

<sup>11</sup>Lupus and Vasculitis Unit, Addenbrooke's Hospital, Cambridge, UK

<sup>12</sup>Lupus Research Unit, The Rayne Institute, St Thomas' Hospital London UK

<sup>13</sup>Division of Women's Health, King's College London, UK.

<sup>14</sup>Section of Renal Medicine and Vascular Inflammation, Division of Immunology and Inflammation, Department of Medicine, Imperial College London, London, UK

<sup>15</sup>LUPUS UK, Romford, Essex, UK

<sup>16</sup>Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, UK

<sup>17</sup>Division of Women's Health, King's College London, UK

<sup>18</sup>Centre for Rheumatology, University College London, London, UK

**Correspondence to:** Caroline Gordon, Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham Research Laboratories, New Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2WB;  
[p.c.gordon@bham.ac.uk](mailto:p.c.gordon@bham.ac.uk)

**Sir,**

We are grateful to Guillermo Ruiz-Irastorza and colleagues for their very positive comments (1) about the British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults(2). Regarding their comments suggesting that we might have been more radical regarding the dose and duration of corticosteroids we would like to emphasise that we did state in the main text of the executive summary(3) and in the full guideline(2), as well as in our table in both documents suggesting dosing regimens for active disease and maintenance therapy, that the lowest effective dose should be used at all times.

We are well aware of the toxicity of high dose corticosteroids and that many patients will respond to doses well below 1mg/kg/day for severe flares. However there is considerable variation in dosing required in different patients with various lupus manifestations, particularly if they are already on corticosteroids. If intravenous pulses are not being used for any reason, oral doses of prednisolone or equivalent in the range of up to 0.75-1 mg/kg/day may be required for life-threatening conditions unresponsive to the lower dose such as up to 0.5mg/kg/day as suggested first in the table. We specifically recommend in the main guideline section on severe lupus therapy with corticosteroids(2) that the lower dose oral and intravenous regimens should be used rather than the higher doses that have been used in the past. We never suggested that prednisolone doses greater than 30mg/day were required for any specific indication.

We did not quote the paper by Ruiz-Arruza et al.(4) as it was published in early June 2015, just after we ran our last literature search for corticosteroids and we can only apologise that we did not pick this up later and for any other omissions. However this paper and other reports of corticosteroid regimens used in lupus nephritis mentioned by Ruiz-Irastorza et al.(1) do not address or exclude the need for patients with very severe lung, cardiac, gastrointestinal, haematological and neuro-psychiatric lupus requiring higher dose corticosteroid regimens, particularly as the entry criteria for the study reported by Riuz-Arruza et al.(4) was a SLEDAI score of only 6 or more.

We did not provide any specific recommendations for tapering corticosteroids in non-renal lupus as there was little evidence for a reliable strategy for all lupus patients when we defined the topics for our literature review. This is certainly a topic worthy of further discussion in

the light of new evidence in a future revision of the guideline and we did emphasise reduction to a safer target dose of  $\leq 7.5$  mg/kg/day to avoid complications of corticosteroid therapy so we would not expect patients to be exposed to high doses for long periods of time. In the section on key standards of care at the end of the main guideline we discuss again the importance of using the least amount of corticosteroids possible and the importance of adjusting therapy if treatment is not producing the desired effect within the expected time frame to reduce the risk of accumulation of chronic damage.

## REFERENCES

- (1) Ruiz-Irastorza G, Ugarte A, Ruiz-Arruza I, Erdozain JG, Gonzalez-Echavarri C., Soto A. Comments to the British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. *Rheumatology (Oxford)* 2018;
- (2) Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D'Cruz D et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. *Rheumatology (Oxford)* 2018; 57(1):e1-e45.
- (3) Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D'Cruz D et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. *Rheumatology (Oxford)* 2018; 57(1):14-8.
- (4) Ruiz-Arruza I, Barbosa C, Ugarte A, Ruiz-Irastorza G. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. *Autoimmun Rev* 2015; 14(10):875-9.